ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag us supreme court neuroscience developmental biology disease medicine

Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Notebook
The Scientist Staff | Dec 7, 1997 | 7 min read
November was a rollercoaster month at the National Academy of Sciences (NAS). First, the United States Supreme Court declined to hear NASA's appeal of a lower court ruling subjecting the academy and its committees to the Federal Advisory Committees Act (FACA) of 1972. Animal rights groups argued that under FACA there should have been more public representation on a committee set up to revise the NIH Guide for the Care and Use of Laboratory Animals (R. Finn, The Scientist, July 22, 1996, page 1)
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Into the Limelight
Kate Yandell | Oct 1, 2015 | 8 min read
Glial cells were once considered neurons’ supporting actors, but new methods and model organisms are revealing their true importance in brain function.
Genetic And Molecular Mysteries Of Sleep Are Keeping Researchers Alert
Alison Mack | Oct 27, 1996 | 9 min read
SIDEBAR : Sleep Research Resources Some consider sleep an unavoidable nuisance; others, a sweet indulgence. For the most part, though, we take our slumber for granted, rarely considering why we spend a hefty chunk of our lives unconscious. But for sleep researchers, that question represents a supreme mystery. Exactly what purpose sleep serves, as well as how the body regulates sleeping and waking, remain largely unknown. Behavioral scientists and physiologists have pursued these questions for
A Question of Chimeras
Clare Kittredge(ckittredge@the-scientist.com) | Apr 10, 2005 | 6 min read
Looking to cure a host of neurodegenerative diseases, StemCells, a Palo Alto, Calif.-based company, has transplanted human neural stem cells into the brains of thousands of mice.
Cloning Capsized?
Ted Agres | Aug 19, 2001 | 10+ min read
Biopharmaceutical researchers fear how pending federal legislation outlawing the cloning of human cells will restrict their abilities to find cures for major degenerative diseases.1,2 Some also see lawmakers impinging on established nonhuman cloning techniques essential for the discovery of new drugs and therapies. The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) th
Stem Cell Researchers Take on Parkinson's
Laura Defrancesco | May 27, 2001 | 6 min read
Parkinson's disease could be the perfect target for stem cell therapy. The etiology of this progressively debilitating disease is clear: scientists know what cells are affected, where those cells reside, when those cells are created during development, and what their target is. This information is reported in scores of articles on cell transplantation that use fetal cells to treat Parkinson's in animal models and people. The good news continues. New research shows that by using stem cells, sci
Notebook
Eugene Russo | Dec 5, 1999 | 7 min read
Contents Pivotal pump Leptin limbo Clue to obesity Biotech Web site Helping hand Mapping malaria Notebook Pictured above are pigmented bacterial colonies of Deinococcus radiodurans, the most radiation-resistant organism currently known. DEINO-MITE CLEANUP In 1956, investigators discovered a potentially invaluable cleanup tool in an unlikely place. A hardy bacterium called Deinococcus radiodurans unexpectedly thrived in samples of canned meat thought to be sterilized by gamma radiation. The b
Notebook
The Scientist Staff | Apr 26, 1998 | 8 min read
WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were

Run a Search

ADVERTISEMENT